<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cancersp</journal-id><journal-title-group><journal-title xml:lang="ru">Южно-Российский онкологический журнал/ South Russian Journal of Cancer</journal-title><trans-title-group xml:lang="en"><trans-title>South Russian Journal of Cancer</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2686-9039</issn><publisher><publisher-name>АНО "Перспективы онкологии"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37748/2686-9039-2024-5-1-2</article-id><article-id custom-type="edn" pub-id-type="custom">INMJLZ</article-id><article-id custom-type="elpub" pub-id-type="custom">cancersp-256</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Экспрессия микроРНК-34, микроРНК-130, микроРНК-148, микроРНК-181, микроРНК-194 и микроРНК-605 в ткани опухоли ободочной кишки</article-title><trans-title-group xml:lang="en"><trans-title>MicroRNA-34, microRNA-130, microRNA-148, microRNA-181, microRNA-194 and microRNA-605 expression in colon cancer tissue</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7375-9585</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Азовский</surname><given-names>Д. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Azovsky</surname><given-names>D. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Азовский Даниил Игоревич – б/c, б/з, врач-онколог отделения абдоминальной онкологии, Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук», г. Томск, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7375-9585" ext-link-type="uri">https://orcid.org/0000-0001-7375-9585</ext-link>, SPIN: 1540-2016, AuthorID: 1059659</p></bio><bio xml:lang="en"><p>Daniil I. Azovsky – MD, oncologist physician at the Abdominal Oncology Department, Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7375-9585" ext-link-type="uri">https://orcid.org/0000-0001-7375-9585</ext-link>, SPIN: 1540-2016, AuthorID: 1059659</p></bio><email xlink:type="simple">azovdaniil@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4701-0375</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьев</surname><given-names>С. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Afanasyev</surname><given-names>S. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Афанасьев Сергей Геннадьевич – д.м.н., профессор, заведующий отделением абдоминальной онкологии, Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук», г. Томск, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-4701-0375" ext-link-type="uri">https://orcid.org/0000-0002-4701-0375</ext-link>, SPIN: 9206-3037, AuthorID: 264236, ResearcherID: D-2084-2012, Scopus Author ID: 21333316900</p></bio><bio xml:lang="en"><p>Sergei G. Afanasyev – Dr. Sci. (Med.), professor, Head of the Abdominal Oncology Department, Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-4701-0375" ext-link-type="uri">https://orcid.org/0000-0002-4701-0375</ext-link>, SPIN: 9206-3037, AuthorID: 264236, ResearcherID: D-2084-2012, Scopus Author ID: 21333316900</p></bio><email xlink:type="simple">afanasievsg@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3796-7218</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Августинович</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Avgustinovich</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Августинович Александра Владимировна – к.м.н., старший научный сотрудник отделения абдоминальной онкологии, Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук», г. Томск, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3796-7218" ext-link-type="uri">https://orcid.org/0000-0003-3796-7218</ext-link>, SPIN: 2952-6119, AuthorID: 558788</p></bio><bio xml:lang="en"><p>Alexandra V. Avgustinovich – Cand. Sci. (Med.), Senior Researcher at the Department of Abdominal Oncology, Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3796-7218" ext-link-type="uri">https://orcid.org/0000-0003-3796-7218</ext-link>, SPIN-2952-6119, AuthorID: 558788</p></bio><email xlink:type="simple">aov862@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5269-736X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Спирина</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Spirina</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Спирина Людмила Викторовна – д.м.н., ведущий научный сотрудник лаборатории биохимии опухолей, Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук», г. Томск, Российская Федерация; заведующий кафедрой биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, г. Томск, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-5269-736X" ext-link-type="uri">https://orcid.org/0000-0002-5269-736X</ext-link>, SPIN: 1336-8363, AuthorID: 441893, ResearcherID: A-7760-2012, Scopus Author ID: 36960462500</p></bio><bio xml:lang="en"><p>Liudmila V. Spirina – Dr. Sci. (Med.), Leading Researcher at the Laboratory of Tumor Biochemistry, Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, Russian Federation; Head of the Department of Biochemistry and Molecular Biology with a course in clinical laboratory diagnostics, Siberian State Medical University, Tomsk, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-5269-736X" ext-link-type="uri">https://orcid.org/0000-0002-5269-736X</ext-link>, SPIN: 1336-8363, AuthorID: 441893, ResearcherID: A-7760-2012, Scopus Author ID: 36960462500</p></bio><email xlink:type="simple">spirinalvl@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2964-9041</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалева</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovaleva</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ковалева Ирина Владимировна – лаборант-исследователь лаборатории биохимии опухолей, Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук», г. Томск, Российская Федерация; ассистент кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики, ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, г. Томск, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-2964-9041" ext-link-type="uri">https://orcid.org/0000-0003-2964-9041</ext-link>, SPIN: 9737-7086, AuthorID: 1076520, Scopus Author ID: 57215197522</p></bio><bio xml:lang="en"><p>Irina V. Kovaleva – laboratory assistant-researcher at the Laboratory of Tumor Biochemistry, Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, Russian Federation; Assistant at the Department of Biochemistry and Molecular Biology with a course in clinical laboratory diagnostics, Siberian State Medical University, Tomsk, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-2964-9041" ext-link-type="uri">https://orcid.org/0000-0003-2964-9041</ext-link>, SPIN: 9737-7086, AuthorID: 1076520, Scopus Author ID: 57215197522</p></bio><email xlink:type="simple">irina.kovalyova.kovaleva@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1126-5890</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зиннурова</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Zinnurova</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зиннурова Алина Борисовна – студент, ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, г. Томск, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0009-0006-1126-5890" ext-link-type="uri">https://orcid.org/0009-0006-1126-5890</ext-link></p></bio><bio xml:lang="en"><p>Alina B. Zinnurova – student, Siberian State Medical University, Tomsk, Russian Federation.</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0009-0006-1126-5890" ext-link-type="uri">https://orcid.org/0009-0006-1126-5890</ext-link></p></bio><email xlink:type="simple">lina.zinnurova@bk.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-9820-9636</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Belova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белова Виктория Андреевна – студент, ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, г. Томск, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0009-0007-9820-9636" ext-link-type="uri">https://orcid.org/0009-0007-9820-9636</ext-link>, AuthorID: 600452</p></bio><bio xml:lang="en"><p>Victoria A. Belova – student, Siberian State Medical University, Tomsk, Russian Federation.</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0009-0007-9820-9636" ext-link-type="uri">https://orcid.org/0009-0007-9820-9636</ext-link>, AuthorID: 600452</p></bio><email xlink:type="simple">emailkf@yandex.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences"</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»; &#13;
ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences"; &#13;
Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Научно-исследовательский институт онкологии – филиал ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»; ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute – branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences"; Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>21</day><month>02</month><year>2024</year></pub-date><volume>5</volume><issue>1</issue><fpage>17</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Азовский Д.И., Афанасьев С.Г., Августинович А.В., Спирина Л.В., Ковалева И.В., Зиннурова А.Б., Белова В.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Азовский Д.И., Афанасьев С.Г., Августинович А.В., Спирина Л.В., Ковалева И.В., Зиннурова А.Б., Белова В.А.</copyright-holder><copyright-holder xml:lang="en">Azovsky D.I., Afanasyev S.G., Avgustinovich A.V., Spirina L.V., Kovaleva I.V., Zinnurova A.B., Belova V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cancersp.com/jour/article/view/256">https://www.cancersp.com/jour/article/view/256</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Определение экспрессии микроРНК‑34, микроРНК‑130, микроРНК‑148, микроРНК‑181, микроРНК‑194 и микроРНК‑605 в ткани опухоли ободочной кишки в зависимости от клинико-морфологических особенностей опухоли и эффективности лечения.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование было включено 56 пациентов с диагнозом колоректальный рак в возрасте от 43 до 75 лет (средний возраст составил 54 года). Пациенты получали хирургическое или комбинированное лечение, включая неоадъювантную химиотерапию с учетом местной распространенности процесса, в клиниках НИИ онкологии Томского НИМЦ. Экспрессию микроРНК определяли методом полимеразной цепной реакции (ПЦР) в реальном времени.</p></sec><sec><title>Результаты</title><p>Результаты. Получены данные о связи микроРНК‑130 с размером опухоли. Развитие регионарных метастазов было ассоциировано с изменением микроРНК‑130, микроРНК‑194 и микроРНК‑605. Уровень гистологической организации опухоли был связан с микроРНК‑34, микроРНК‑130, микроРНК‑148, а ответ на терапию – с микроРНК‑130, микроРНК‑148 и микроРНК‑605. Кроме того, по данным исследования была выявлена значимость микроРНК‑130, которая связана с распространением опухоли, гистологической дифференцировкой и ответом на противоопухолевую терапию.</p></sec><sec><title>Заключение</title><p>Заключение. Выявлены особенности экспрессии микроРНК‑34, микроРНК‑130, микроРНК‑148, микроРНК‑181, микроРНК‑194 и микроРНК‑605, ассоциированные с клинико-морфологическими особенностями опухоли ободочной кишки. Отмечены корреляционные зависимости между исследуемыми показателями, которые, вероятно, определяют исход и прогноз заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. Determination of the expression of microRNA‑34, microRNA‑130, microRNA‑148, microRNA‑181, microRNA‑194 and microRNA‑605 in colon tumor tissue depending on the clinical and morphological features of the tumor and the effectiveness of treatment.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 56 patients diagnosed with colorectal cancer aged 43 to 75 years with the average age of 54 years. Taking into account the local prevalence of the process patients received surgical or combined treatment, including neoadjuvant chemotherapy, in the clinics of the Cancer Research Institute, Tomsk NRMC. MicroRNA expression was determined by polymerase chain reaction (PCR) in real time.</p></sec><sec><title>Results</title><p>Results. The obtained information revealed the relation of microRNA‑130 to the tumor size. The development of regional metastases was associated with changes in microRNA‑130, microRNA‑194 and microRNA‑605. The level of histological organization of the tumor was associated with microRNA‑34, microRNA‑130, microRNA‑148, and the response to therapy – with microRNA‑130, microRNA‑148 and microRNA‑605. In addition, according to the study, the significance of microRNA‑130 was revealed, which is associated with tumor spread, histological differentiation and response to antitumor therapy.</p></sec><sec><title>Conclusion</title><p>Conclusion. The features of expression of microRNA‑34, microRNA‑130, microRNA‑148, microRNA‑181, microRNA‑194 and microRNA‑605 associated with clinical and morphological features of colon tumors were revealed. Correlations between the studied indicators are noted, which probably determine the outcome and prognosis of the disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>колоректальный рак</kwd><kwd>микроРНК-34</kwd><kwd>микроРНК-130</kwd><kwd>микроРНК-148</kwd><kwd>микроРНК-181</kwd><kwd>микроРНК-194</kwd><kwd>микроРНК-605</kwd><kwd>распространенность заболевания</kwd><kwd>эффект лечения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>colorectal cancer</kwd><kwd>microRNA-34</kwd><kwd>microRNA-130</kwd><kwd>microRNA-148</kwd><kwd>microRNA-181</kwd><kwd>microRNA-194</kwd><kwd>microRNA-605</kwd><kwd>prevalence of the disease</kwd><kwd>treatment effect</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–976. https://doi.org/10.2147/CIA.S109285</mixed-citation><mixed-citation xml:lang="en">Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–976. https://doi.org/10.2147/CIA.S109285</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Poturnajova M, Furielova T, Balintova S, Schmidtova S, Kucerova L, Matuskova M. Molecular features and gene expression signature of metastatic colorectal cancer (Review). Oncol Rep. 2021 Apr;45(4):10. https://doi.org/10.3892/or.2021.7961</mixed-citation><mixed-citation xml:lang="en">Poturnajova M, Furielova T, Balintova S, Schmidtova S, Kucerova L, Matuskova M. Molecular features and gene expression signature of metastatic colorectal cancer (Review). Oncol Rep. 2021 Apr;45(4):10. https://doi.org/10.3892/or.2021.7961</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wang B, Shen Z long, Gao Z dong, Zhao G, Wang C you, Yang Y, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle. 2015;14(7):1046–1058. https://doi.org/10.1080/15384101.2015.1007767</mixed-citation><mixed-citation xml:lang="en">Wang B, Shen Z long, Gao Z dong, Zhao G, Wang C you, Yang Y, et al. MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway. Cell Cycle. 2015;14(7):1046–1058. https://doi.org/10.1080/15384101.2015.1007767</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014 Apr;124(4):1853–1867. https://doi.org/10.1172/jci73531</mixed-citation><mixed-citation xml:lang="en">Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014 Apr;124(4):1853–1867. https://doi.org/10.1172/jci73531</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Jin L, Rong W, Meng F, Wang X, Wang S, et al. Expression and significance of miR-34 with PI3K, AKT and mTOR proteins in colorectal adenocarcinoma tissues. Cell Mol Biol (Noisy-le-grand). 2022 Sep 30;68(9):57–62. https://doi.org/10.14715/cmb/2022.68.9.9</mixed-citation><mixed-citation xml:lang="en">Li Y, Jin L, Rong W, Meng F, Wang X, Wang S, et al. Expression and significance of miR-34 with PI3K, AKT and mTOR proteins in colorectal adenocarcinoma tissues. Cell Mol Biol (Noisy-le-grand). 2022 Sep 30;68(9):57–62. https://doi.org/10.14715/cmb/2022.68.9.9</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Miao C, Zhang J, Zhao K, Liang C, Xu A, Zhu J, et al. The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis. Oncotarget. 2017 Jun 27;8(26):43344–43355. https://doi.org/10.18632/oncotarget.17949</mixed-citation><mixed-citation xml:lang="en">Miao C, Zhang J, Zhao K, Liang C, Xu A, Zhu J, et al. The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis. Oncotarget. 2017 Jun 27;8(26):43344–43355. https://doi.org/10.18632/oncotarget.17949</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mei H, Wen Y. MicroRNAs for Diagnosis and Treatment of Colorectal Cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(1):47–55. https://doi.org/10.2174/1871530320999200818134339</mixed-citation><mixed-citation xml:lang="en">Mei H, Wen Y. MicroRNAs for Diagnosis and Treatment of Colorectal Cancer. Endocr Metab Immune Disord Drug Targets. 2021;21(1):47–55. https://doi.org/10.2174/1871530320999200818134339</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sukocheva OA, Liu J, Neganova ME, Beeraka NM, Aleksandrova YR, Manogaran P, et al. Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers. Semin Cancer Biol. 2022 Nov;86(Pt 2):358–375. https://doi.org/10.1016/j.semcancer.2022.05.012</mixed-citation><mixed-citation xml:lang="en">Sukocheva OA, Liu J, Neganova ME, Beeraka NM, Aleksandrova YR, Manogaran P, et al. Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers. Semin Cancer Biol. 2022 Nov;86(Pt 2):358–375. https://doi.org/10.1016/j.semcancer.2022.05.012</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Спирина Л. В., Тарасова А. С., Добродеев А. Ю., Костромицкий Д. Н., Августинович А. В., Афанасьев С. Г. и др. Молекулярные маркеры развития колоректального рака, связь с объективным ответом опухоли на лечение. Вопросы онкологии. 2022;68(1):85–90. https://doi.org/10.37469/0507-3758-2022-68-1-85-90, EDN: STKSOQ</mixed-citation><mixed-citation xml:lang="en">Spirina LV, Tarasova AS, Dobrodeev AYu, Kostromitskii DN, Avgustinovich AV, Afanas’ev SG, et al. Molecular markers of colorectal cancer, association with objective tumor response to treatment. Problems in Oncology. 2022;68(1):85–90. (In Russ.). https://doi.org/10.37469/0507-3758-2022-68-1-85-90, EDN: STKSOQ</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li J, Tian F, Li D, Chen J, Jiang P, Zheng S, et al. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 2014 Sep 17;588(18):3491–3500. https://doi.org/10.1016/j.febslet.2014.08.008</mixed-citation><mixed-citation xml:lang="en">Li J, Tian F, Li D, Chen J, Jiang P, Zheng S, et al. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 2014 Sep 17;588(18):3491–3500. https://doi.org/10.1016/j.febslet.2014.08.008</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Peng Z, Duan F, Yin J, Feng Y, Yang Z, Shang J. Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test. J Transl Med. 2019 Oct 22;17(1):347. https://doi.org/10.1186/s12967-019-2093-y</mixed-citation><mixed-citation xml:lang="en">Peng Z, Duan F, Yin J, Feng Y, Yang Z, Shang J. Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test. J Transl Med. 2019 Oct 22;17(1):347. https://doi.org/10.1186/s12967-019-2093-y</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs. 2014 Mar;25(3):346–352. https://doi.org/10.1097/cad.0000000000000049</mixed-citation><mixed-citation xml:lang="en">Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs. 2014 Mar;25(3):346–352. https://doi.org/10.1097/cad.0000000000000049</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rezaei T, Amini M, Hashemi ZS, Mansoori B, Rezaei S, Karami H, et al. microRNA-181 serves as a dual-role regulator in the development of human cancers. Free Radic Biol Med. 2020 May 20;152:432–454. https://doi.org/10.1016/j.freeradbiomed.2019.12.043</mixed-citation><mixed-citation xml:lang="en">Rezaei T, Amini M, Hashemi ZS, Mansoori B, Rezaei S, Karami H, et al. microRNA-181 serves as a dual-role regulator in the development of human cancers. Free Radic Biol Med. 2020 May 20;152:432–454. https://doi.org/10.1016/j.freeradbiomed.2019.12.043</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chang HY, Ye SP, Pan SL, Kuo TT, Liu BC, Chen YL, et al. Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer. Theranostics. 2017;7(16):3889–3900. https://doi.org/10.7150/thno.20041</mixed-citation><mixed-citation xml:lang="en">Chang HY, Ye SP, Pan SL, Kuo TT, Liu BC, Chen YL, et al. Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer. Theranostics. 2017;7(16):3889–3900. https://doi.org/10.7150/thno.20041</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tang K, Wu Z, Sun M, Huang X, Sun J, Shi J, et al. Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice. Cancer Lett. 2022 Mar 31;529:53–69. https://doi.org/10.1016/j.canlet.2021.12.033</mixed-citation><mixed-citation xml:lang="en">Tang K, Wu Z, Sun M, Huang X, Sun J, Shi J, et al. Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice. Cancer Lett. 2022 Mar 31;529:53–69. https://doi.org/10.1016/j.canlet.2021.12.033</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, et al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol. 2014 Mar;67(3):198–203. https://doi.org/10.1136/jclinpath-2013-201904</mixed-citation><mixed-citation xml:lang="en">Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, et al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol. 2014 Mar;67(3):198–203. https://doi.org/10.1136/jclinpath-2013-201904</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yang X, Sun Y, Zhang Y, Han S. Downregulation of miR 181b inhibits human colon cancer cell proliferation by targeting CYLD and inhibiting the NF κB signaling pathway. Int J Mol Med. 2020 Nov;46(5):1755–1764. https://doi.org/10.3892/ijmm.2020.4720</mixed-citation><mixed-citation xml:lang="en">Yang X, Sun Y, Zhang Y, Han S. Downregulation of miR 181b inhibits human colon cancer cell proliferation by targeting CYLD and inhibiting the NF κB signaling pathway. Int J Mol Med. 2020 Nov;46(5):1755–1764. https://doi.org/10.3892/ijmm.2020.4720</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Liu T, Fang Y. MiR-194-3p modulates the progression of colorectal cancer by targeting KLK10. Histol Histopathol. 2022 Mar;37(3):301–309. https://doi.org/10.14670/hh-18-413</mixed-citation><mixed-citation xml:lang="en">Liu T, Fang Y. MiR-194-3p modulates the progression of colorectal cancer by targeting KLK10. Histol Histopathol. 2022 Mar;37(3):301–309. https://doi.org/10.14670/hh-18-413</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao J, Wang Y, Wang Y, Gao J, Wu X, Li H. miR-194-3p represses the docetaxel resistance in colon cancer by targeting KLK10. Pathol Res Pract. 2022 Aug;236:153962. https://doi.org/10.1016/j.prp.2022.153962</mixed-citation><mixed-citation xml:lang="en">Zhao J, Wang Y, Wang Y, Gao J, Wu X, Li H. miR-194-3p represses the docetaxel resistance in colon cancer by targeting KLK10. Pathol Res Pract. 2022 Aug;236:153962. https://doi.org/10.1016/j.prp.2022.153962</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sahu SS, Dey S, Nabinger SC, Jiang G, Bates A, Tanaka H, et al. The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis. Sci Rep. 2019 Nov 1;9(1):15803. https://doi.org/10.1038/s41598-019-52225-2</mixed-citation><mixed-citation xml:lang="en">Sahu SS, Dey S, Nabinger SC, Jiang G, Bates A, Tanaka H, et al. The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis. Sci Rep. 2019 Nov 1;9(1):15803. https://doi.org/10.1038/s41598-019-52225-2</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Spirina LV, Avgustinovich AV, Afanas’ev SG, Cheremisina OV, Volkov MY, Choynzonov EL, et al. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy. Curr Drug Targets. 2020;21(7):713–721. https://doi.org/10.2174/1389450120666191127113854</mixed-citation><mixed-citation xml:lang="en">Spirina LV, Avgustinovich AV, Afanas’ev SG, Cheremisina OV, Volkov MY, Choynzonov EL, et al. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy. Curr Drug Targets. 2020;21(7):713–721. https://doi.org/10.2174/1389450120666191127113854</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang G, Wu YJ, Yan F. MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9480–9488. https://doi.org/10.26355/eurrev_201911_19442</mixed-citation><mixed-citation xml:lang="en">Zhang G, Wu YJ, Yan F. MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9480–9488. https://doi.org/10.26355/eurrev_201911_19442</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
